累积膀胱壁剂量与接受立体定向每日自适应磁共振引导放疗的前列腺癌患者报告急性泌尿毒性相关
纳入130例在1.5 T磁共振直线加速器上接受立体定向体部放疗的前列腺癌患者,通过可变形图像配准进行剂量累积,评估累积膀胱(壁)剂量与患者报告的急性泌尿毒性(国际前列腺症状评分增加≥10分和/或3个月内开始使用α受体阻滞剂)的关联。膀胱D5cm3、V10-35Gy(%)和Dmean以及膀胱壁V10-35Gy(cm3和%)和Dmean与结局相关(比值比1.04-1.33,P值0.001-0.044);校正基线特征后,膀胱V10-35Gy(%)和Dmean以及膀胱壁V10-35Gy(cm3和%)和Dmean仍与结局相关(比值比1.04-1.30,P值0.001-0.028)。膀胱壁参数通常显示更大的AUC值。
要点
- 39例(30%)患者出现临床相关的IPSS增加和/或开始使用α受体阻滞剂。
- 膀胱壁V10-35Gy(cm3和%)和Dmean与患者报告的急性泌尿毒性相关,校正后仍相关。
- 膀胱壁剂量参数是预测患者报告泌尿毒性的有前景参数,需前瞻性验证。
核心结论
- 这是首个评估累积膀胱壁剂量与接受磁共振引导立体定向体部放疗的前列腺癌患者报告泌尿毒性相关性的研究。
- 膀胱壁剂量是预测患者报告泌尿毒性的有前景参数,因此值得前瞻性验证并在治疗计划中考虑。
研究设计与样本
- 纳入130例接受1.5 T磁共振直线加速器治疗的前列腺癌患者。
- 患者在接受治疗前、治疗后1个月和3个月填写国际前列腺症状评分问卷。
- 通过基于可变形图像配准的剂量累积重建实际递送剂量。
主要发现
- 39例患者(30%)出现临床相关的IPSS增加(≥10分)和/或3个月内开始使用α受体阻滞剂。
- 膀胱D5cm3、V10-35Gy(%)、Dmean以及膀胱壁V10-35Gy(cm3和%)、Dmean与结局相关(比值比1.04-1.33,P值0.001-0.044)。
- 校正基线特征后,膀胱V10-35Gy(%)和Dmean以及膀胱壁V10-35Gy(cm3和%)和Dmean仍与结局相关(比值比1.04-1.30,P值0.001-0.028)。
- 膀胱壁参数通常显示更大的AUC值。
局限性
- 原文结论指出该发现值得前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Magnetic resonance (MR)-guided linear accelerators (MR-Linac) enable accurate estimation of delivered doses through dose accumulation using daily MR images and treatment plans. We aimed to assess the association between the accumulated bladder (wall) dose and patient-reported acute urinary toxicity in prostate cancer (PCa) patients treated with stereotactic body radiation therapy (SBRT). MATERIALS AND METHODS: One-hundred-and-thirty PCa patients treated on a 1.5 T MR-Linac were included. Patients filled out International Prostate Symptom Scores (IPSS) questionnaires at baseline, 1 month, and 3 months post-treatment. Deformable image registration-based dose accumulation was performed to reconstruct the delivered dose. Dose parameters for both bladder and bladder wall were correlated with a clinically relevant increase in IPSS (≥ 10 points) and/or start of alpha-blockers within 3 months using logistic regression. RESULTS: Thirty-nine patients (30%) experienced a clinically relevant IPSS increase and/or started with alpha-blockers. Bladder D5cm3, V10-35Gy (in %), and Dmean and Bladder wall V10-35Gy (cm3 and %) and Dmean were correlated with the outcome (odds ratios 1.04-1.33, p-values 0.001-0.044). Corrected for baseline characteristics, bladder V10-35Gy (in %) and Dmean and bladder wall V10-35Gy (cm3 and %) and Dmean were still correlated with the outcome (odds ratios 1.04-1.30, p-values 0.001-0.028). Bladder wall parameters generally showed larger AUC values. CONCLUSION: This is the first study to assess the correlation between accumulated bladder wall dose and patient-reported urinary toxicity in PCa patients treated with MR-guided SBRT. The dose to the bladder wall is a promising parameter for prediction of patient-reported urinary toxicity and therefore warrants prospective validation and consideration in treatment planning.
引用
- Willigenburg T, van der Velden JM, Zachiu C, et al. Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy. Radiother Oncol. 2022. PMID: 35489444. doi:10.1016/j.radonc.2022.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。